At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
montelukast +1 moredrug
Likely dose
montelukast 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart Disease
In Brief
A clinical study evaluating montelukast and Placebo for Coronary Heart Disease. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a particular substance involved in inflammation, called leukotrienes, is involved in causing heart disease to occur or to progress.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease
CountriesUnited States
CollaboratorsAmerican Heart Association
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedSep 2006
Primary CompletionJul 2009
Study CompletionAug 2009
TodayJul 2026
First PostedSep 22, 2006
Enrollment StartJul 1, 2006
Primary CompletionJul 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.8 years ago
Interventions
montelukastdrug
10 mg tablet (masked by capsule) daily for 1 month
Placebodrug
1 lactose-containing capsule daily for 1 month